IL-RF-IDEAS
13.7.2021 15:02:14 CEST | Business Wire | Press release
rf IDEAS, a leading manufacturer of credential readers for authentication and logical access, is proud to announce that it is the recipient of the 2021 HP Partner Award for Partner Agility.
Presented at the virtually held HP Developer Partner Conference 2021, this award recognizes rf IDEAS for its role in helping HP land a successful worldwide deployment deal, featuring readers with Bluetooth® Low Energy technology, for its development agility, and for managing the changes and challenges over the past year. “This award represents the great relationship we have built with HP,” said David Cottingham, president of rf IDEAS. “We were able to take secure authentication to the next level by deploying a solution that combines mobile credentials and secure physical employee badges. Through a difficult year, we have been able to execute on tough delivery timelines and offer continued support to HP and their customers long after the product leaves our warehouse.”
For the last 13 years, rf IDEAS and HP partnered together to provide leading authentication technology for HP’s Secure Print solutions for many top enterprise companies in multiple verticals around the world. During this time, rf IDEAS has built a robust supply chain to support HP in multiple routes to market such as direct MPS or indirect channel through worldwide distributors.
“The pandemic caused many new technical and logistical hurdles to overcome to deliver a highly complex and customized solution. Being able to adapt to an ever-changing environment in a positive, productive way requires real partnership, flexibility and a commitment to win,” said Paul Birkett, leader of HP’s Commercial Software Solutions for its print business. “rf IDEAS responsiveness to HP’s rapidly evolving customer needs is what made them stand out. rf IDEAS was instrumental in our work with this critical customer, and without the work of this partner, we would not have won a global multimillion-dollar Managed Print Services Deal.”
This is the fifth time HP has awarded to rf IDEAS for various achievements including Customer Focus in 2020, Partner Sales Excellence in 2017, Partner Collaboration in Excellence in 2016 and Partner in Excellence in 2014.
Learn more about rf IDEAS Secure Print solutions (link: https://www.rfideas.com/solutions/secure-print-management ).
About rf IDEAS
rf IDEAS, Inc. is a leader in logical access solutions for healthcare, manufacturing, government, education and enterprise. The company’s WAVE ID® readers (formerly pcProx®) are trusted by users across the globe and backed by strong partnerships with leading identity access management providers. rf IDEAS readers enable innovative solutions for single sign-on, secure printing, attendance tracking and mobile authentication while supporting nearly all credentials worldwide. For more information, visit www.rfIDEAS.com .
rf IDEAS® is a registered trademark of rf IDEAS, Inc. All other trademarks, service marks and product or service names are property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005095/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom